Visible Genetics Q1 Revenues Dip as Service Revenues Drop | GenomeWeb

NEW YORK, May 10 – Visible Genetics of Toronto said Thursday its first quarter revenues slipped slightly to $3.57 million, compared with $3.64 million in the year ago period, as an increase in product sales failed to offset a sharp drop in revenues from services.

During the quarter, however, the clinical genomics company said sales of its genotyping kits and consumables rose 85 percent from the year ago quarter. The company did not offer a dollar figure for sales of these products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.